Schrdinger, Inc. provides a physics-based software platform that enables the discovery of novel molecules for drug development and material applications. The company is headquartered in New York, New York.
| Revenue (TTM) | $259.04M |
| Gross Profit (TTM) | $147.31M |
| EBITDA | $-147.58M |
| Operating Margin | -70.60% |
| Return on Equity | -16.20% |
| Return on Assets | -14.40% |
| Revenue/Share (TTM) | $3.50 |
| Book Value | $4.51 |
| Price-to-Book | 6.65 |
| Price-to-Sales (TTM) | 8.33 |
| EV/Revenue | 7.26 |
| EV/EBITDA | -10.82 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 7.50% |
| Shares Outstanding | $65.64M |
| Float | $57.33M |
| % Insiders | 3.00% |
| % Institutions | 96.87% |
Volatility is currently expanding
Schrödinger, Inc. has undergone significant changes, including pipeline cuts and a strategic pivot away from solo clinical development. Despite software growth deceleration and pipeline setbacks, SDGR's financials improved with the Ajax sale and a stronger balance sheet. SDGR's net income turned positive in Q2 2026, aided by a $48.9M gain from Ajax and increased cash reserves to $418.8M.
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on September 13, 2026, the company granted restricted stock units (RSUs) with respect to 2,243 shares of the company's common stock to three newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducem.
Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Schrodinger (SDGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
NEW YORK--(BUSINESS WIRE)---- $SDGR #AI--Schrödinger announced the formation of Tectora, a biotech it co-founded with NEA and RA Capital, focused on immunology and inflammation therapies.
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The live presentation will take place on Monday, September 14, 2026 at 1:05 p.m. E.T. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery wi.
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement t.
Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript
Schrodinger NASDAQ: SDGR said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers, while the company launched early access for Bunsen, its agentic AI co-scientist.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SDGR and any ticker you trade — then tracks every position and per-strategy win rate.
